{
  "ticker": "OIL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975375",
  "id": "02975375",
  "pages": 13,
  "price_sensitive": true,
  "date": "20250731",
  "time": "1523",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250731/pdf/06md21lq2p3yf7.pdf",
  "summary": "### **Optiscan Imaging Ltd (ASX:OIL) \u2013 Material Information Summary**  \n**Announcement Type: Appendix 4C (Quarterly Activities & Cashflow Report)**  \n\n#### **Operational Highlights:**  \n- **Clinical Milestone:** Initiated first in-human breast cancer study using **InVue\u00ae** (precision surgery) and **InForm\u2122** (digital pathology) devices at Royal Melbourne Hospital. Study aims to support US FDA submissions (50-patient cohort).  \n- **New Product Launch:** Unveiled **InSpecta\u2122**, a veterinary imaging device, expanding addressable market (US veterinary sector valued at ~$11.92B in 2022).  \n- **Strategic Collaboration:** Signed exclusive agreement with **Long Grove Pharmaceuticals** for access to contrast agent **AK-FLUOR\u00ae**, critical for US FDA regulatory submissions.  \n- **R&D Progress:**  \n  - Completed MVP for cloud-based telepathology software (real-time remote pathology imaging).  \n  - Advanced robotic surgery collaboration with **Mayo Clinic** (prototypes developed for breast cancer procedures).  \n\n#### **Financial Highlights (Q2 2025):**  \n- **Cash Flow:** Net operating cash outflow of **($2.322m)** (R&D spend: $1.527m).  \n- **Cash Balance:** **$4.553m** at quarter-end (~1.96 quarters of funding based on current burn).  \n- **Revenue:** Customer receipts **$0.03m** (up QoQ); FY25 YTD receipts **$1.06m** (vs. $0.906m FY24).  \n\n#### **Key Risks/Liquidity Note:**  \n- **Funding Runway:** ~2 quarters of cash remaining; management notes ability to raise capital if needed.  \n\n**No material capital raising or trading halt details identified.**  \n\n---  \n*Summary excludes non-material operational updates, governance details, and forward-looking commentary.*",
  "usage": {
    "prompt_tokens": 7965,
    "completion_tokens": 401,
    "total_tokens": 8366,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T05:45:44.598183"
}